Nuance Biotech, a China-based specialty pharmaceutical company, today announced series B fundraising of US$20 million with additional capital US$15 million tied to its acquisition of new products, led by C-Bridge Capital, a private equity firm focused on Chinese healthcare market.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
